DE69708121T2 - Halogenid-enthaltende insulinzubereitungen - Google Patents

Halogenid-enthaltende insulinzubereitungen

Info

Publication number
DE69708121T2
DE69708121T2 DE69708121T DE69708121T DE69708121T2 DE 69708121 T2 DE69708121 T2 DE 69708121T2 DE 69708121 T DE69708121 T DE 69708121T DE 69708121 T DE69708121 T DE 69708121T DE 69708121 T2 DE69708121 T2 DE 69708121T2
Authority
DE
Germany
Prior art keywords
halogenide
insulin preparations
containing insulin
preparations
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69708121T
Other languages
English (en)
Other versions
DE69708121D1 (de
DE69708121T3 (de
Inventor
Elsebeth Norup
Liselotte Langkjaer
Svend Havelund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8096378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69708121(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE69708121D1 publication Critical patent/DE69708121D1/de
Application granted granted Critical
Publication of DE69708121T2 publication Critical patent/DE69708121T2/de
Publication of DE69708121T3 publication Critical patent/DE69708121T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69708121T 1996-06-20 1997-06-19 Halogenid-enthaltende insulinzubereitungen Expired - Lifetime DE69708121T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK68596 1996-06-20
DK68596 1996-06-20
EP97928123A EP0921812B2 (de) 1996-06-20 1997-06-19 Halogenid-enthaltende insulinzubereitungen
PCT/DK1997/000268 WO1997048414A1 (en) 1996-06-20 1997-06-19 INSULIN PREPARATIONS CONTAINING NaCl

Publications (3)

Publication Number Publication Date
DE69708121D1 DE69708121D1 (de) 2001-12-13
DE69708121T2 true DE69708121T2 (de) 2002-08-01
DE69708121T3 DE69708121T3 (de) 2012-05-16

Family

ID=8096378

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69708121T Expired - Lifetime DE69708121T3 (de) 1996-06-20 1997-06-19 Halogenid-enthaltende insulinzubereitungen

Country Status (21)

Country Link
EP (1) EP0921812B2 (de)
JP (2) JP4404380B2 (de)
KR (1) KR100451778B1 (de)
CN (1) CN1120019C (de)
AT (1) ATE208208T1 (de)
AU (1) AU720484B2 (de)
BR (1) BR9709845B1 (de)
CA (1) CA2258097C (de)
CZ (1) CZ297937B6 (de)
DE (1) DE69708121T3 (de)
DK (1) DK0921812T4 (de)
ES (1) ES2167751T5 (de)
HU (1) HU228094B1 (de)
IL (2) IL127366A0 (de)
NO (1) NO324430B1 (de)
PL (1) PL189964B1 (de)
PT (1) PT921812E (de)
RU (1) RU2182015C2 (de)
UA (1) UA49890C2 (de)
WO (1) WO1997048414A1 (de)
ZA (1) ZA975470B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
ATE259653T1 (de) * 1998-11-18 2004-03-15 Novo Nordisk As Stabile wässrige insulinzubereitungen ohne phenol und kresol
JP2002535287A (ja) * 1999-01-26 2002-10-22 イーライ・リリー・アンド・カンパニー 単分散性６量体のアシル化されたインスリンアナログ製剤
AU4937699A (en) * 1999-04-05 2000-10-23 Olga Evgenievna Kolesova Use of succinic acid or salts thereof for the treatment of diabetes mellitus andwound healing
EP1523993A1 (de) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptidzusammensetzungen mit verbesserter Stabilität
ES2236010T3 (es) * 1999-12-16 2005-07-16 Eli Lilly And Company Composiciones de polipeptidos con estabilidad mejorada.
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
CA2581798A1 (en) 2004-10-05 2006-04-13 Petter Lybeck A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AU2013368990B2 (en) * 2012-12-26 2017-05-18 Wockhardt Limited Pharmaceutical composition
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
RU2016132386A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных
AU2015205620A1 (en) * 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116527B (da) * 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
US4783441A (en) † 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4439181A (en) * 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
AU550068B2 (en) † 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PT93057B (pt) * 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DE122006000015I1 (de) * 1993-06-21 2006-06-29 Novo Nordisk As Asp-B28-Insulinkristalle
AU682061B2 (en) * 1993-09-17 1997-09-18 Novo Nordisk A/S Acylated insulin
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations

Also Published As

Publication number Publication date
CA2258097C (en) 2011-02-08
CN1120019C (zh) 2003-09-03
ES2167751T5 (es) 2012-03-30
BR9709845A (pt) 1999-08-10
JP4404380B2 (ja) 2010-01-27
CZ395698A3 (cs) 1999-05-12
JP2009235075A (ja) 2009-10-15
DE69708121D1 (de) 2001-12-13
DE69708121T3 (de) 2012-05-16
IL127366A0 (en) 1999-10-28
NO324430B1 (no) 2007-10-15
AU3253697A (en) 1998-01-07
HUP9904031A2 (hu) 2000-04-28
HU228094B1 (en) 2012-10-29
AU720484B2 (en) 2000-06-01
PL330763A1 (en) 1999-05-24
NO985981D0 (no) 1998-12-18
ATE208208T1 (de) 2001-11-15
DK0921812T4 (da) 2012-04-02
CN1222083A (zh) 1999-07-07
CA2258097A1 (en) 1997-12-24
NO985981L (no) 1998-12-18
HUP9904031A3 (en) 2000-10-30
CZ297937B6 (cs) 2007-05-02
EP0921812B2 (de) 2011-12-21
RU2182015C2 (ru) 2002-05-10
DK0921812T3 (da) 2002-02-11
IL127366A (en) 2007-07-04
KR100451778B1 (ko) 2004-11-16
PT921812E (pt) 2002-04-29
PL189964B1 (pl) 2005-10-31
ES2167751T3 (es) 2002-05-16
KR20000022031A (ko) 2000-04-25
BR9709845B1 (pt) 2008-11-18
EP0921812A1 (de) 1999-06-16
WO1997048414A1 (en) 1997-12-24
JP2000513344A (ja) 2000-10-10
UA49890C2 (uk) 2002-10-15
EP0921812B1 (de) 2001-11-07
ZA975470B (en) 1997-12-22

Similar Documents

Publication Publication Date Title
DE69708121D1 (de) Halogenid-enthaltende insulinzubereitungen
DK0428038T3 (da) Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
PT758248E (pt) Formulacoes para o factor ix
DK0751959T3 (da) Modificerede polypeptider med forøget biologisk aktivitet
DE69021387D1 (de) Medizinische aerosolformulierungen.
DE69737995D1 (de) INSULINPREPARATION MIT MAnnitol
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ATE275940T1 (de) Medizinische aerosolformulierungen von formoterol
ES2192839T3 (es) Timosina beta 4 oxidada.
DE69715482T2 (de) Herstellung von 1,1,1,3,3-Pentachlorbutan und von 1,1,1,3,3-Pentafluorbutan
ATE11547T1 (de) Neue d-homosteroide, ihre verwendung und herstellung, sowie pharmazeutische praeparate damit.
DE68923860T2 (de) Derivate von Alkoholen und Ethern.
ATE92542T1 (de) Azeotropaehnliche zusammensetzungen von 1,1dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1fluor|than.
ES2152315T3 (es) Xamoneline tartrato.
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
FR2707492B1 (fr) Nouvelles compositions cosmétiques ou dermatologiques renfermant les ribosomes, préparation des ribosomes, préparation desdites compositions et leur application.
DE3878087T2 (de) 2-hydroxybenzophenon-hydrazide und derivate davon.
FR2696926B1 (fr) Prothèse totale du genou du type intracondylienne.
DK0730861T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til fremstilling af farmaceutiske præparater, der er nyttige til behandli
ATE80143T1 (de) Isomere formyl-trimethylbicyclo(2,2,2)oct-7-ene.
IT9041649A0 (it) Protettore della cornea e metodo per il suo ottenimento.
NO164539C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt 5-nafthyl-2,4-dimethyl-3h-1,2,4-triazol-3-thion.
NO903705D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n-disubstituerte arylcykloalkylaminer.
ATE101194T1 (de) Azeotropaehnliche zusammensetzungen von 1,3dichlor-1,1,2,2,3-pentafluorpropan und 2-methyl-2-propanol.

Legal Events

Date Code Title Description
8363 Opposition against the patent
R102 Epo decision maintaining patent in amended form now final

Ref document number: 921812

Country of ref document: EP

R102 Epo decision maintaining patent in amended form now final

Ref document number: 921812

Country of ref document: EP

Effective date: 20111221